Semaglutide Semaglutide is a long-acting GLP-1 RA approved both globally to treat type 2 diabetes and long-term weight management in obese or overweight patients aged 12 years and older - consistent with liraglutide
Additionally, 92 percent experienced less mental fog, 86 percent reported reduced anxiety, and 81 percent said they slept better
Bring documentation
Laraia BA, Adler NE, Coleman-Phox K, Vieten C, Mellin L, Kristeller JL, Thomas M, Stotland N, Lustig RH, Dallman MF, Hecht FM, Bush N, DeGroat CL, Epel ES: Novel Interventions to reduce stress and overeating in overweight pregnant women: a feasibility study (submitted)
What You Can Do Now If you are currently on a weekly GLP-1 injectable and struggling with adherence , speak with your prescriber about your specific barrier whether that is needle anxiety, scheduling difficulty, or side effects
doi: 10.2337/db18-1123 17 ChristensenMVedtofteLHolstJJVilsbllTKnopFK